

Nonenzymatic free radical-catalyzed generation of 15-deoxy- $\Delta^{12,14}$ -prostaglandin J₂-like compounds (deoxy-J₂-isoprostanes) in vivo¹

Klarissa D. Hardy,*[†] Brian E. Cox,* Ginger L. Milne,* Huiyong Yin,* and L. Jackson Roberts II^{2,*[†]}

Division of Clinical Pharmacology,* and Department of Pharmacology,[†] Vanderbilt University School of Medicine, Nashville, TN 37232

Abstract 15-Deoxy- $\Delta^{12,14}$ -prostaglandin J₂ (15-d-PGJ₂) is a reactive cyclopentenone eicosanoid generated from the dehydration of cyclooxygenase-derived prostaglandin D₂ (PGD₂). This compound possesses an α,β -unsaturated carbonyl moiety that can readily adduct thiol-containing biomolecules such as glutathione and cysteine residues of proteins via the Michael addition. Due to its reactivity, 15-d-PGJ₂ is thought to modulate inflammatory and apoptotic processes and is believed to be an endogenous ligand for peroxisome proliferator-activated receptor- γ . However, the extent to which 15-d-PGJ₂ is formed in vivo and the mechanisms that regulate its formation are unknown. Previously, we have reported the formation of PGD₂ and PGJ₂-like compounds, termed D₂/J₂-isoprostanes (D₂/J₂-IsoPs), produced in vivo by the free radical-catalyzed peroxidation of arachidonic acid (AA). Based on these findings, we investigated whether 15-d-PGJ₂-like compounds are also formed via this nonenzymatic pathway. Here we report the generation of novel 15-d-PGJ₂-like compounds, termed deoxy-J₂-isoprostanes (deoxy-J₂-IsoPs), in vivo, via the nonenzymatic peroxidation of AA. Levels of deoxy-J₂-IsoPs increased 12-fold (6.4 ± 1.1 ng/g liver) in rats after oxidant insult by CCl₄ treatment, compared with basal levels (0.55 ± 0.21 ng/g liver). These compounds may have important bioactivities in vivo under conditions associated with oxidant stress.—Hardy, K. D., B. E. Cox, G. L. Milne, H. Yin, and L. Jackson Roberts II. **Nonenzymatic free radical-catalyzed generation of 15-deoxy- $\Delta^{12,14}$ -prostaglandin J₂-like compounds (deoxy-J₂-isoprostanes) in vivo.** *J. Lipid Res.* 2011. 52: 113–124.

Supplementary key words 15-d-PGJ₂ • cyclopentenone eicosanoid • lipid peroxidation • oxidant stress • isoprostane

This research was supported by National Institutes of Health Grants GM15431 and ES13125. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health. K.D.H. is supported by National Institutes of Health Ruth L. Kirschstein National Research Service Award 1F31AG035483-01 from the National Institute of Aging.

Manuscript received 2 August 2010 and in revised form 7 October 2010.

Published, JLR Papers in Press, October 13, 2010
DOI 10.1194/jlr.M010264

Copyright © 2011 by the American Society for Biochemistry and Molecular Biology, Inc.

This article is available online at <http://www.jlr.org>

Cyclooxygenase 1 (COX-1) and COX-2 catalyze the committed step in the formation of prostaglandins (PG) from arachidonic acid (AA) by generating the unstable bicyclic endoperoxide intermediate, PGH₂ (1–3). Tissue-specific synthases convert PGH₂ to the parent PGs PGE₂, PGD₂, PGI₂, and thromboxane (TXA₂) (1). These molecules are formed in response to various stimuli, and they exert a plethora of biological effects through interaction with cell surface receptors (1).

PGE₂ and PGD₂ are unstable and readily undergo dehydration in an aqueous solution to form cyclopentenone PGs PGA₂ and PGJ₂, respectively. Dehydration of PGE₂ results in formation of PGA₂ (4). Dehydration of PGD₂ results in the formation of PGJ₂ (5). PGJ₂ can isomerize in vitro in the presence of albumin to Δ^{12} -PGJ₂ and then undergo dehydration to yield 15-deoxy- $\Delta^{12,14}$ -PGJ₂ (15-d-PGJ₂) (Fig. 1) (5). Unlike other classes of PGs, cyclopentenone PGs are characterized by the presence of an electrophilic α,β -unsaturated carbonyl moiety in the prostane ring, rendering them susceptible to Michael addition with nucleophilic biomolecules, such as the free thiols of glutathione (GSH) and cysteine residues of proteins (6). These compounds have attracted considerable attention because they exhibit a unique spectrum of biological activities, presumably through reaction with cellular biomolecules (6). 15-d-PGJ₂, one of the most well-defined cyclopentenone

Abbreviations: AA, arachidonic acid; AAPH, 2,2'-azobis (amidinopropane)dihydrochloride; APCI, atmospheric pressure chemical ionization; CID, collision-induced dissociation; COX, cyclooxygenase; GSH, glutathione; GST, glutathione S-transferase; HPLC, high-performance liquid chromatography; IsoPs, isoprostanes; NF- κ B, nuclear factor kappa B; PC, phosphatidylcholine; PG, prostaglandin; PLA2, phospholipase A₂; PPAR- γ , peroxisome proliferator-activated receptor- γ ; RT, retention time; SIM, selected ion monitoring; SRM, selected reaction monitoring; TXA₂, thromboxane.

¹This article is dedicated to the memory of Dr. Jason Morrow and to his mentorship and scientific guidance in the studies described herein.

²To whom correspondence should be addressed.
email: jack.roberts@vanderbilt.edu




Fig. 1. 15-d-PGJ₂ is formed from PGD₂ through a sequence of dehydration and isomerization reactions.

PGs, is particularly reactive because it possesses two electrophilic carbon centers that are susceptible to nucleophilic attack: one center is in the cyclopentenone ring (C-9), and the other is on the lower side chain (C-13). This compound is believed to mediate a number of cellular responses through covalent interaction with critical intracellular protein targets (7, 8). 15-d-PGJ₂ is postulated to be an endogenous ligand of peroxisome proliferator-activated receptor- γ (PPAR- γ), which plays an important role in adipocyte differentiation and antiinflammatory processes (9). 15-d-PGJ₂ has also been shown to exhibit antiinflammatory, antiproliferative, and proapoptotic activities independent of PPAR- γ in studies performed *in vitro*. However, the extent to which 15-d-PGJ₂ is formed *in vivo* and the mechanisms regulating its formation remain unclear.

Oxidant stress has been increasingly implicated in the pathogenesis of a number of human diseases, including atherosclerosis, cancer, neurodegenerative disorders, and even the normal aging process (10–13). Lipid peroxidation is a central feature of oxidant stress. We have previously reported discovery of PG-like compounds, termed isoprostanates (IsoP), which are produced *in vivo* from free radical-induced peroxidation of AA, independent of COX (14). IsoPs are isomeric to PGs, differing in the stereochemical relationships of the two side chains on the prostane ring. PG side chains are in the *trans* configuration with respect to the prostane ring, whereas the majority of IsoP side chains are in the *cis* configuration. Additionally, unlike PGs, IsoPs are initially formed *in situ* in phospholipids and are then subsequently hydrolyzed to their free form by phospholipases (15, 16). The mechanism for the formation of IsoPs from AA has been well defined. Following abstraction of a bisallylic hydrogen from AA and the addition of a molecule of oxygen to form a peroxy radical, the radical undergoes 5-*exo* cyclization, and a second molecule of oxygen is added to the backbone of the compound to form PGG₂-like compounds (17, 18). These unstable bicycloendoperoxide intermediates can be reduced to PGF_{2 α} -like compounds, termed F₂-IsoPs (14), or they undergo rearrangement to PGE₂- and PGD₂-like compounds (E₂/D₂-IsoPs) (19) or TXA₂-like compounds (Tx-IsoPs). Based on this mechanism of formation, four regioisomers of each class of IsoPs derived from AA are generated, each of which can theoretically be composed of eight racemic diastereomers. Compounds are denoted 5-, 8- 12-, or 15-

series regioisomers depending on the carbon atom to which the side chain hydroxyl is attached (20).

The extent to which cyclopentenone prostanoids are generated *in vivo* has been the subject of continuing controversy for the last 3 decades (21–24). We have previously reported that, analogous to the formation of PGA₂ and PGJ₂ from the dehydration of COX-generated PGE₂ and PGD₂, respectively, cyclopentenone IsoPs (A₂/J₂-IsoPs) are also formed *in vivo* from the dehydration of E₂/D₂-IsoPs (25). However, evidence for the formation of 15-d-PGJ₂ *in vivo* is lacking. Hirata et al. (21) reported that the precursor of 15-d-PGJ₂, Δ^{12} -PGJ₂, can be detected in human urine and that its formation is suppressed to some extent by COX inhibitors. Levels of free 15-d-PGJ₂ excreted in human urine were found to be very low (22). Heretofore, it has been assumed that synthesis of 15-d-PGJ₂ depends upon COX generation of PGD₂. Given their structural and functional similarity, it is highly likely that similar to the dehydration of COX-derived PGD₂, D₂-IsoPs can undergo dehydration and isomerization to yield a series of 15-d-PGJ₂-like compounds, termed deoxy-J₂-IsoPs. A proposed mechanism for formation of the four regioisomers of deoxy-J₂-IsoPs is shown in Fig. 2. It should be noted that dehydration of the 15- series D₂-IsoPs followed by isomerization of the 13,14 double bond would result in loss of the chiral center at C-12, eliminating the stereochemical orientation of the lower side chain that distinguishes IsoPs from PGs. A single chiral center would be retained at C-8. Thus, a compound identical in all respects to 15-d-PGJ₂ and its corresponding enantiomer would be expected to form from dehydration and isomerization of 15-D₂-IsoP (Fig. 3). For purposes of discussion hereafter, the PG possessing a structure identical to that generated by COX is referred to as 15-d-PGJ₂. The compound that is enantiomeric to COX-derived 15-d-PGJ₂ is referred to as *ent*-15-d-PGJ₂. The racemic mixture is termed *rac*-15-d-PGJ₂. Dehydration of other regioisomers of D₂-IsoPs yields various regioisomers of deoxy-J₂-IsoPs (Fig. 2).

Herein, we report that 15-d-PGJ₂ and 15-d-PGJ₂-like compounds (deoxy-J₂-IsoPs) are formed in significant abundance *in vitro* and *in vivo* via the nonenzymatic free radical-catalyzed peroxidation of AA, independent of COX enzymes. The finding that a series of deoxy-J₂-IsoPs are generated *in vivo* through lipid peroxidation is of potential biological importance due to the predicted bioactivity




Fig. 2. Proposed pathway for the formation of the deoxy-J₂-IsoPs via the nonenzymatic peroxidation of AA. For simplicity, the stereochemistry of both the lipid peroxidation intermediates and final IsoPs are not shown.

of these compounds. Similar to 15-d-PGJ₂, each of the deoxy-J₂-IsoPs possesses reactive electrophilic carbon centers, which render them susceptible to nucleophilic addition reactions with thiol-containing biomolecules, such as GSH and cysteine residues of proteins. Because the biological effects of 15-d-PGJ₂ are often likely to be mediated by the compound's reactivity with cellular thiols, all of the deoxy-J₂-IsoPs would be expected to exert similar biological effects in vivo under settings of oxidant stress.

MATERIALS AND METHODS

Chemical reagents and supplies

Human serum albumin, CCl₄, triphenyl-phosphine (TPP), and *Apis mellifera* venom phospholipase A₂ (PLA₂) were purchased from Sigma-Aldrich. PGD₂, 15-d-PGJ₂, and isotopically labeled 15-d-PGJ₂ ([²H₄]15-d-PGJ₂) was purchased from Cayman Chemical Co. (Ann Arbor, MI). Arachidonic acid was purchased from NU-Check Prep, Inc. (Elysian, MN). The C₁₈ Sep-Paks were purchased from Waters Corporation (Milford, MA). High-performance liquid

chromatography (HPLC) columns were purchased from Phenomenex (Torrance, CA). All solvents were of HPLC quality and were purchased from EM Science (Gibbstown, NJ).

Oxidation of AA in vitro

Five mg of AA was dissolved in 50 μl of ethanol and added immediately to 4.95 ml of phosphate-buffered saline (PBS) (pH 7.4) containing 10 mM 2,2'-azobis(amidinopropane)dihydrochloride




Fig. 3. Structures of *rac*-15-d-PGJ₂, consisting of 15-d-PGJ₂ and its enantiomer.

(AAPH), a free radical initiator. The AA oxidation reaction mixture was incubated at 37°C for 24 h. Following oxidation, excess triphenylphosphine (TPP) was added to the oxidized AA mixture (1 mg/ml) for 5 min at room temperature to reduce hydroperoxides to hydroxyls. Subsequently, the oxidized AA sample was extracted twice with 2 ml of ethyl acetate, and extracts were dried under nitrogen gas. Samples were stored in 200 μ l of ethanol at -80°C until analyzed by LC/tandem mass spectrometry (MS/MS).

Isolation of 15-d-PGJ₂-like compounds (deoxy-J₂-IsoPs) from rat liver

CCl₄ (1 mg/kg body weight in 1 ml of corn oil) was administered orogastrically to male Sprague-Dawley rats to induce lipid peroxidation (14). Control animals received corn oil alone. Four hours after treatment, the animals were anesthetized with pentobarbital (60 mg/kg, intraperitoneally) and euthanized. Livers were removed and immediately flash-frozen in liquid nitrogen and stored at -80°C . Tissues samples weighing 300–500 mg were homogenized in 5 ml of ice-cold chloroform-methanol (2:1, v/v) containing butylated hydroxytoluene (0.005%) to prevent ex vivo autooxidation. Esterified deoxy-J₂-IsoPs in liver phospholipids were enzymatically hydrolyzed with *A. mellifera* venom PLA₂ to liberate free deoxy-J₂-IsoPs. Subsequently, free IsoPs were extracted over a C₁₈ Sep-Pak cartridge that had been preconditioned by rinsing with methanol and deionized water, pH 3. The C₁₈ Sep-Pak cartridge was rinsed with 10 ml each of deionized water (pH 3) and heptane, and the sample was eluted with 10 ml of 1:1 ethyl acetate-heptane. The solvent was removed by evaporation under a stream of N₂, and samples were stored in 200 μ l of ethanol at -80°C until LC/MS/MS analysis.

Analysis of 15-d-PGJ₂-like compounds (deoxy-J₂-IsoPs) by LC/MS/MS

After oxidized AA was extracted by using the C₁₈ Sep-Pak method described above, the sample was suspended in 100 μ l of 2:1 methanol-water, and deoxy-J₂-IsoPs were analyzed by reverse-phase HPLC. Online HPLC was carried out using a Surveyor MS pump equipped with a Phenomenex Luna C₁₈ column (50 \times 2.00 mm, 3 μ m) at a flow rate of 0.3 ml/min starting with 80% Phase 1 (water-phase 2-acetic acid, 95:5:0.1) to 30% from 1 to 27.0 min and holding at 100% Phase 2 (acetonitrile-methanol-acetic acid, 95:5:0.1) from 28.0 to 29.0 min and returning to 80% Phase 1 at 30.0 to 32.0 min. LC/electrospray ionization (ESI)-MS/MS was carried out with a ThermoFinnigan TSQ/Quantum Ultra mass spectrometer. The ESI source was fitted with a deactivated fused silica capillary (100- μ m inner diameter), and the mass spectrometer was operated in the negative ion mode. Nitrogen was used as both the sheath gas and the auxiliary gas, at 31 and 17 psi, respectively. The capillary temperature was 300°C. The spray voltage was 5.0 kV, and the tube lens voltage was 80 V. In another set of experiments, deoxy-J₂-IsoPs were analyzed by normal phase HPLC/atmospheric pressure chemical ionization (APCI)-MS for separation of deoxy-J₂-IsoP regioisomers. For these experiments, deoxy-J₂-IsoPs were extracted by C₁₈ Sep-Pak chromatography as described previously, and samples were resuspended in mobile phase (93:7, hexane-isopropanol-acetic acid) for normal phase HPLC. Online HPLC was carried out using a Waters Alliance HPLC equipped with a Phenomenex Luna silica column (250 \times 4.60 mm, 5 μ m) at a flow rate of 1.0 ml/min with an isocratic gradient of 93:7:0.1, hexane-isopropanol-acetic acid for 20 min. LC/APCI-MS was carried out with a ThermoFinnigan TSQ/Quantum Ultra mass spectrometer operating in the negative ion mode with an APCI source. MS/MS analyses using collision-induced dissociation (CID) of the precursor ion m/z of 315 of putative 15-d-PGJ₂ and deoxy-J₂-IsoPs were performed from 18 to 27 eV

under 1.5 mTorr of argon. Spectra shown were obtained at 24 eV. Spectra were displayed by averaging scans across chromatographic peaks. Selected reaction monitoring (SRM) was performed according to the characteristic fragmentation patterns of 15-d-PGJ₂ determined by CID. The collision energy for SRM was 24 eV. Data acquisition and analysis were performed using Xcaliber version 2.0 software.

Adduction of deoxy-J₂-IsoPs with glutathione in vitro

To isolate deoxy-J₂-IsoPs in vitro, AA was oxidized as described above and extracted with ethyl acetate. The sample was dried under a stream of N₂ and reconstituted in 100 μ l of ethanol. This sample was dissolved in 0.5 ml of 1 N HCl and incubated for 5 h at 37°C to facilitate acid-catalyzed dehydration of D₂/J₂-IsoPs to deoxy-J₂-IsoPs. Following incubation, the reaction mixture was diluted to 10 ml with 50 mM aqueous ammonium acetate (pH 3.4) and extracted three times with 1.5–2 ml of ethyl acetate. Extracts were pooled, dried under a stream of N₂, and reconstituted in 100 μ l of ethanol. This sample was dissolved in 1 ml of PBS (pH 6.5) and incubated in the presence of excess reduced GSH (\sim 1 mg) and \sim 1 mg of equine liver glutathione S-transferase (GST) for 2 h at 37°C. A similar method was used for the incubation of chemically synthesized 15-d-PGJ₂ in the presence of GSH and GST. After the incubation, GSH adducts of deoxy-J₂-IsoPs and synthesized 15-d-PGJ₂ were purified by extraction using a C₁₈ Sep-Pak cartridge preconditioned with 10 ml of acetonitrile and 50 mM aqueous ammonium acetate (pH 3.4) and eluted with 10 ml of 95% ethanol, and dried under a stream of N₂. Samples were suspended in a 3:1 mixture of Phase 1-Phase 2 (Phase 1, water-phase 2-acetic acid, 95:5:0.1; Phase 2, acetonitrile-methanol-acetic acid, 95:5:0.1), and deoxy-J₂-IsoP-GSH adducts were definitively identified by LC/ESI-MS/MS. The reverse-phase HPLC conditions described above were used. For MS/MS experiments, CID analysis of the parent ion m/z 622 of 15-d-PGJ₂-GSH adduct and putative deoxy-J₂-IsoP-GSH adducts was performed at 18 to 22 eV under 1.5 mTorr of argon. Spectra shown were obtained at 22 eV.

RESULTS

Formation and characterization of 15-d-PGJ₂ and 15-d-PGJ₂-like compounds in vitro

A representative selected ion monitoring (SIM) chromatogram obtained from LC/MS/MS analysis of chemically synthesized 15-d-PGJ₂ is shown in **Fig. 4A** (upper chromatogram). When analyzed by ESI-MS in the negative ion mode, the predicted precursor ion for 15-d-PGJ₂ is m/z 315. The peak eluting at 19.4 min was analyzed by CID, and predicted fragments were obtained (**Fig. 4A**, lower spectrum). These included m/z 271 [$\text{M} - \text{CO}_2$]⁻ and m/z 203 (**Fig. 4A**, lower spectrum). The smaller peak in the upper chromatogram is likely a synthetic isomer of 15-d-PGJ₂ as results from LC/ESI-MS/MS analysis of this peak were identical to that of the authentic 15-d-PGJ₂.

AA was then oxidized in vitro using the free radical initiator AAPH, and extracts were analyzed for 15-d-PGJ₂ and other 15-d-PGJ₂-like compounds (deoxy-J₂-IsoPs). When analyzed by LC/ESI-MS/MS in negative ion mode, the predicted precursor ion for deoxy-J₂-IsoPs is m/z 315. The SIM chromatogram of this ion is shown in **Fig. 4B**. As is evident, multiple chromatographic peaks are present that presumably represent different deoxy-J₂-IsoP regioisomers obtained from the nonenzymatic peroxidation of AA. The chromatographic




Fig. 4. LC/ESI-MS/MS analysis of 15-d-PGJ₂ (A) and a mixture of 15-d-PGJ₂-like compounds (deoxy-J₂-IsoPs) obtained from the nonenzymatic oxidation of AA in vitro (B). A: LC/ESI-MS/MS analysis of a chemically synthesized 15-d-PGJ₂ employing SIM (upper chromatogram) and CID (lower product ion spectrum). B: LC/ESI-MS/MS analysis of 15-d-PGJ₂-like compounds obtained from the in vitro oxidation of AA employing SIM for the precursor ion *m/z* 315 (upper chromatogram) and CID (lower product ion spectrum) indicative of putative 15-d-PGJ₂.

peak eluting at 20.0 min has nearly the same retention time as authentic 15-d-PGJ₂. An authentic sample of isotopically labeled 15-d-PGJ₂ ([²H₄]15-d-PGJ₂) showed the identical retention time upon co-injection (see below). (Analyses described in legends to Fig. 4A and B were performed on separate days, accounting for differences in LC retention time.) This peak was analyzed by CID to obtain

structural information, and the CID spectrum is shown in Fig. 4B. The observed product ions, *m/z* 271 and *m/z* 203, are consistent with fragmentation of 15-d-PGJ₂. The series of compounds representing deoxy-J₂-IsoPs elute in multiple chromatographic peaks at approximately 19–22 min. CID analysis of this series of chromatographic peaks supports the contention that these are 15-d-PGJ₂-like compounds

derived from different IsoP regioisomers, including compounds of the 5-, 8-, 12-, and 15-series (Fig. 5). The composite CID spectrum obtained by summing scans over the entire series of chromatographic peaks reveals the product ion m/z 271 $[M - CO_2]^-$ as well as product ions resulting from specific fragmentation of each of the four deoxy-J₂-IsoPs regioisomers, including m/z 217 (5-series), m/z 95 (8-series), m/z 175 (12-series), and m/z 203 (15-series). Additionally, we used normal phase HPLC to obtain chromatographic separation of each of the deoxy-J₂-IsoPs regioisomers. Shown in Fig. 6 is a representative chromatogram of the different regioisomers of deoxy-J₂-IsoPs analyzed by normal phase LC/APCI-MS/MS. Again, CID analysis of the series of chromatographic peaks is consistent with fragmentation of each of the deoxy-J₂-IsoP regioisomers (Fig. 6).

Due to their nonenzymatic formation, compounds generated from the free radical-catalyzed peroxidation of AA would be predicted to be racemic. Thus, 15-series deoxy-J₂-IsoPs are predicted to comprise a racemic mixture of a compound identical in all respects to COX-derived 15-d-PGJ₂ and its enantiomer, *ent*-15-d-PGJ₂. The racemic mixture is referred to as *rac*-15-d-PGJ₂ (Fig. 3). To confirm the formation of *rac*-15-d-PGJ₂ from the nonenzymatic oxidation of AA, we used LC/MS/MS analysis with SRM. The major product ion unique to *rac*-15-d-PGJ₂ is m/z 203; thus, we monitored the precursor-to-product transition of m/z 315 to m/z 203 to selectively detect *rac*-15-d-PGJ₂. [²H₄]15-d-PGJ₂ (*d*₄-15-d-PGJ₂) was used as an internal standard for these analyses. The precursor ion of *d*₄-15-d-PGJ₂ is m/z 319 due to the presence of four deuterium atoms on the upper side chain of the molecule, and CID analysis of *d*₄-15-d-PGJ₂ yields the major product ions m/z 275 $[M - CO_2]^-$ and m/z 203 (data not shown). Shown in Fig. 7 is a representative chromatogram for the SRM analysis of *rac*-15-d-

PGJ₂ generated from the nonenzymatic oxidation of AA, and these compounds coelute with *d*₄-15-d-PGJ₂. Additional support for the identification of these compounds as 15-d-PGJ₂ and *ent*-15-d-PGJ₂ was obtained through LC/ultraviolet (UV) analysis, which showed that these compounds possess a UV absorbance maximum (λ_{max}) of 306 nm, identical to that of authentic 15-d-PGJ₂ (data not shown). To assess the total amount of deoxy-J₂-IsoPs formed from the nonenzymatic oxidation of AA, LC/MS quantification was performed by measuring the abundance of compounds representing deoxy-J₂-IsoPs relative to that of the *d*₄-15-d-PGJ₂ internal standard. The mass spectrometer was operated in SRM mode in the negative ion mode, monitoring the precursor-to-product transition from m/z 315 to m/z 271 for the deoxy-J₂-IsoPs and monitoring the parent-to-product transition from m/z 319 to m/z 275 for *d*₄-15-d-PGJ₂. Deoxy-J₂-IsoPs are generated in significant abundance from the nonenzymatic oxidation of AA in vitro, and levels are 16.0 ± 3.4 ng/mg AA ($n = 4$). In additional studies, when we oxidized a phospholipid containing *sn*-2-AA (palmitoyl-arachidonyl-phosphatidylcholine [PAPC]) in vitro, we found that 15-d-PGJ₂ was formed on the intact phospholipid (data not shown).

Adduction of deoxy-J₂-IsoPs with GSH in vitro

One of our primary interests in the formation of 15-d-PGJ₂ and cyclopentenone deoxy-J₂-IsoPs in vivo is related to the fact that these molecules contain electrophilic α,β -unsaturated carbonyl moieties which render them susceptible to Michael addition with cellular nucleophiles. Because the biological effects of 15-d-PGJ₂ are thought to be mediated largely through its interaction with cellular thiols, all of the deoxy-J₂-IsoPs would be expected to exert similar biological effects through adduction to cellular thiols. Thus, as a further characterization of these com-




Fig. 5. LC/ESI-MS/MS analysis of multiple regioisomers of deoxy-J₂-IsoPs generated from the nonenzymatic oxidation of AA in vitro. A: Structurally specific fragmentation of the different deoxy-J₂-IsoP regioisomers. B: SIM chromatogram of the precursor ion at m/z 315 (upper) and CID spectrum (lower) obtained by summing scans over the chromatographic peaks, revealing structurally specific fragmentation of the different deoxy-J₂-IsoP regioisomers.




Fig. 6. Normal phase LC/APCI-MS/MS analysis of multiple regioisomers of deoxy-J₂-IsoPs generated from the nonenzymatic peroxidation of AA *in vitro*. SIM chromatogram of the parent ion at *m/z* 315 (upper) and CID spectrum (lower) obtained by summing scans over the series of chromatographic peaks reveals structurally specific fragmentation of the different deoxy-J₂-IsoP regioisomers.

pounds, we sought to determine whether deoxy-J₂-IsoPs would adduct GSH, an abundant cellular thiol, in the presence of GST. We have previously shown that 15-d-PGJ₂ and other cyclopentenone eicosanoids readily adduct GSH in the presence of GST *in vitro* (26–30). In the present study, we incubated deoxy-J₂-IsoPs generated from the nonenzymatic oxidation of AA *in vitro* with GSH in the presence of GST. Adducts were partially purified from an incubation mixture by C₁₈ Sep-Pak extraction and

subjected to LC/MS as described above. Putative deoxy-J₂-IsoP-GSH adducts were definitively identified by LC/ESI-MS/MS. The predicted precursor ion for deoxy-J₂-IsoP-GSH adducts in negative ion mode is *m/z* 622. SIM analysis showed multiple peaks, with this *m/z* eluting from 10.7 to 15.3 min, presumably representing the GSH adducts of different deoxy-J₂-IsoP regioisomers (**Fig. 8A**). These adducts elute at a retention time similar to that of the GSH adduct of 15-d-PGJ₂. CID experiments confirmed




Fig. 7. Analysis of putative *rac*-15-d-PGJ₂ *in vitro* by LC/MS/MS using SRM. LC/MS/MS analysis of *rac*-15-d-PGJ₂ (A) from the nonenzymatic oxidation of AA *in vitro* and chemically synthesized [²H₄]15-d-PGJ₂ (d₄-15-d-PGJ₂) (B). The mass spectrometer was operated in negative ion mode using SRM to monitor the precursor-to-product transition of *m/z* 315–203 for *rac*-15-d-PGJ₂ (chromatogram A) and the precursor-to-product transition of *m/z* 319–203 for d₄-15-d-PGJ₂ (chromatogram B).




Fig. 8. Analysis of GSH adducts of deoxy-J₂-IsoPs and 15-d-PGJ₂ by LC/ESI-MS/MS. A: SIM chromatogram of putative deoxy-J₂-IsoP-GSH adducts with the precursor ion *m/z* 622. B: Composite CID spectrum obtained by summing scans over the series of chromatographic peaks representing deoxy-J₂-IsoP-GSH adducts. C: CID spectrum of the synthesized 15-d-PGJ₂-GSH adduct.

the molecules at *m/z* 622 to be deoxy-J₂-IsoP-GSH adducts. A composite CID spectrum was obtained by summing scans over these peaks (Fig. 8B). The precursor ion, M⁻, is present at *m/z* 622. Relevant product ions include *m/z* 306 [M - deoxy-J₂-IsoP]⁻ (loss of the prostanoid portion of the molecule); *m/z* 272 [M - 350]⁻ (retro-Michael fragmentation); and *m/z* 254 [272 - H₂O]⁻. A similar CID spectrum was observed when chemically synthesized 15-d-PGJ₂ was incubated with GST and GSH (Fig. 8C). It should be noted that the major product ions generated from CID analysis of deoxy-J₂-IsoP-GSH adducts were indistinguishable from those generated from the CID analysis of the synthetic 15-d-PGJ₂-GSH adduct. Together, these data confirm that the molecules putatively identified as cyclopentenone deoxy-J₂-IsoPs are reactive and capable of undergoing nucleophilic addition reactions with GSH.

Isolation and quantification of deoxy-J₂-IsoPs from rat liver

After confirming the formation of *rac*-15-d-PGJ₂ and deoxy-J₂-IsoPs via the nonenzymatic oxidation of AA *in vitro*, we explored whether these compounds are formed *in vivo*.

IsoPs are initially formed *in situ*, esterified in phospholipids, and hydrolyzed to their free form by platelet-activating factor acetylhydrolase and possibly other phospholipases (15). To quantify F₂-IsoPs esterified in tissues, the tissue is initially treated with base to release F₂-IsoPs, which are then quantified. However, base treatment will induce dehydration of D₂-IsoPs to form J₂-IsoPs. Therefore, to quantify esterified deoxy-J₂-IsoPs formed in tissue, the tissue was subjected to enzymatic hydrolysis using bee venom PLA₂. We found that this method of hydrolysis results in <0.3% dehydration of PGD₂ to 15-d-PGJ₂. We have previously shown that treatment of rats with CCl₄ induces a dramatic increase in esterified IsoPs in the liver (19, 25). Therefore, we examined whether deoxy-J₂-IsoPs are formed *in vivo* esterified in liver phospholipids in rats that had been treated with CCl₄. Shown in Fig. 9 is a representative chromatogram from SRM analysis of deoxy-J₂-IsoPs (Fig. 9A), including *rac*-15-d-PGJ₂ (Fig. 9B), generated *in vivo* in liver phospholipids in the rat after CCl₄ treatment. Again, the entire series of deoxy-J₂-IsoPs was quantified by LC/ESI-MS using SRM as described previously. Levels of deoxy-J₂-IsoPs *in vivo* esterified in liver phospholipids in control




Fig. 9. Analysis of putative deoxy-J₂-IsoPs in vivo by LC/MS/MS using SRM. LC/MS/MS analysis of (A) deoxy-J₂-IsoPs regioisomers and (B) the 15-series deoxy-J₂-IsoPs (*rac*-15-d-PGJ₂) generated in vivo esterified in liver phospholipids in rats after treatment with CCl₄ and (C) chemically synthesized [²H₄]15-d-PGJ₂ (d₄-15-d-PGJ₂). The mass spectrometer was operated in the negative ion mode with SRM for the precursor-to-product transitions of *m/z* 315–271 for all deoxy-J₂-IsoPs regioisomers (chromatogram A), *m/z* 315–203 for *rac*-15-d-PGJ₂ (chromatogram B), and *m/z* 319–275 for d₄-15-d-PGJ₂ (chromatogram C).

rats were near the limit of detection (0.55 ± 0.21 ng/g tissue; $n = 5$) for this method. However, in animals treated with CCl₄, levels increased by ~ 12 -fold to 6.4 ± 1.1 ng/g tissue ($n = 5$; $P < 0.0001$ compared with control). Additionally, we have identified phosphatidylcholine (PC) containing esterified 15-d-PGJ₂ (15-d-PGJ₂-PC) generated in vivo in rats after oxidant insult (data not shown). These findings provide evidence that deoxy-J₂-IsoPs are produced in significant abundance in vivo as products of free radical-induced lipid peroxidation.

DISCUSSION

We report finding that a series of 15-d-PGJ₂-like compounds, termed deoxy-J₂-IsoPs, are formed in vitro and in vivo via free radical-catalyzed peroxidation of AA. Among the deoxy-J₂ products formed during this process, the 15-series deoxy-J₂-IsoPs (*rac*-15-d-PGJ₂) comprises a racemic mixture of a molecule identical in all respects to 15-d-PGJ₂ and its corresponding enantiomer. The formation of 15-d-PGJ₂ and 15-d-PGJ₂-like compounds in vivo is biologically relevant because 15-d-PGJ₂ is thought to be an important lipid mediator. Despite significant interest in the bioactivity of 15-d-PGJ₂, the extent to which this compound is formed in vivo and the mechanisms that regulate its

formation have been unclear. In the present study, we have shown for the first time the formation of 15-d-PGJ₂ and 15-d-PGJ₂-like compounds in vivo via free radical-catalyzed lipid peroxidation, independent of the COX pathway. Our results suggest that a second pathway exists for the biosynthesis of 15-d-PGJ₂ in vivo, and these findings provide further insight into the biochemical mechanisms that can contribute to the endogenous generation of reactive lipid mediators.

15-d-PGJ₂ was originally identified as a dehydration product of COX-derived PGD₂ (5). Our initial interest in determining whether 15-d-PGJ₂ and 15-d-PGJ₂-like compounds are formed via the free radical-catalyzed pathway emerged from the observation that cyclopentenone PGA₂ and PGJ₂-like compounds (A₂/J₂-IsoPs) are generated in vivo in significant quantities esterified in liver phospholipids in rats following oxidant insult (25). In addition, recent studies by our laboratory support the contention that PGs can be generated through the IsoP pathway, independent of COX enzymes (31, 32). Gao et al. (31) reported the formation of PGE₂ and PGD₂ and their respective enantiomers in vitro and in vivo through the nonenzymatic peroxidation of AA by epimerization of E₂/D₂-IsoPs, specifically 15-E_{2t}-IsoP and 15-D_{2c}-IsoP, respectively. More recently, Yin et al. (32) reported the formation of PGF_{2 α} in vivo via the IsoP pathway and demonstrated that the majority of putative PGF_{2 α} in human urine is derived from free

radical-initiated peroxidation of AA, independent of COX enzymes. In the present study, we have found that J₂-IsoPs derived from D₂-IsoPs can also undergo further dehydration and isomerization in vivo to yield the cyclopentenone deoxy-J₂-IsoPs. Dehydration of the 15-series J₂-IsoPs yields a compound identical in all respects to COX-derived 15-d-PGJ₂ and its enantiomer.

Cyclopentenone eicosanoids as a class have received considerable attention over the past 3 decades due their reactivity (6, 33). These compounds are characterized by the presence of an electrophilic α,β -unsaturated carbonyl moiety in the prostane ring. This functional group renders them susceptible to nucleophilic addition reactions with thiol-containing biomolecules, which has been attributed to their biological effects. 15-d-PGJ₂, the most extensively studied compound of the cyclopentenone eicosanoids, is particularly reactive due to the presence of two electrophilic carbons. The presence of two electrophilic centers in 15-d-PGJ₂ is thought to contribute to its reactivity and biological potency which are increased compared with those of other cyclopentenone eicosanoids (34). The finding that in addition to 15-d-PGJ₂, a series of deoxy-J₂-IsoPs are formed in significant abundance in vivo is notable due to the fact that these compounds also possess the reactive electrophilic carbon centers that render them susceptible to reaction with cellular nucleophiles. Like other IsoPs generated via the nonenzymatic peroxidation of AA, deoxy-J₂-IsoPs are formed as a series of four regioisomers, each consisting of a mixture of stereoisomers. Deoxy-J₂-IsoPs are derived from the dehydration and isomerization of the different D₂-IsoP and J₂-IsoP regioisomers, including the 5-, 8-, 12-, and 15-series. Of note, the 15-series deoxy-J₂-IsoPs comprise a racemic mixture of 15-d-PGJ₂ and its enantiomer and are termed *rac*-15-d-PGJ₂. Consistent with the presence of the polyunsaturated carbonyl moiety in each of the deoxy-J₂-IsoPs, we have shown that these compounds are reactive and readily undergo nucleophilic addition with GSH. Because this electrophilic reactivity is often likely to be responsible for the bioactivity of 15-d-PGJ₂, all of the deoxy-J₂-IsoPs are expected to have similar bioactivities related to covalent interaction with intracellular proteins. In this regard, the deoxy-J₂-IsoPs represent a new class of lipid peroxidation products that are predicted to have more potent bioactivity than the previously identified cyclopentenone (A₂/J₂) IsoPs, due to the presence of two reactive electrophilic carbons. These compounds may be important lipid mediators involved in the pathophysiology of oxidant stress.


The extent to which both 15-d-PGJ₂ and other deoxy-J₂-IsoPs are produced in vivo is biologically relevant because 15-d-PGJ₂ has been shown to mediate a wide range of biological activities, including modulating inflammatory and apoptotic processes (35–41). Unlike other PGs, which elicit their biological responses by binding specific G-protein-coupled receptors (GPCRs), 15-d-PGJ₂ exerts its biological effects through interaction with key intracellular targets. Some of its activity may relate to the observation that 15-d-PGJ₂ activates the nuclear receptor PPAR- γ (9). Activation of PPAR- γ by 15-d-PGJ₂ has been recently shown

to occur through covalent binding of 15-d-PGJ₂ to a critical cysteine residue in the PPAR- γ ligand binding pocket (42). Additionally, 15-d-PGJ₂ has been shown to inhibit the inflammatory response in a number of cell types, including monocytes and macrophages, by blocking nuclear factor kappa B (NF- κ B)-dependent gene expression via covalent modification of a critical cysteine residue in I κ B kinase and the DNA-binding domains of NF- κ B subunits (38–41). 15-d-PGJ₂ is also thought to be involved in the resolution of inflammation by enhancing apoptosis in activated macrophages through a p38 mitogen-activated protein kinase (MAPK)-dependent increase in reactive oxygen species formation (38). Furthermore, 15-d-PGJ₂ activates the antioxidant response pathway via covalent modification of reactive cysteine residues in Keap1, leading to Nrf2 activation and induction of antioxidant proteins, including HO-1, peroxiredoxin 1, γ -GCL, and heat shock protein 70 (43–47). Finally, 15-d-PGJ₂ has been reported to inhibit proliferation of vascular smooth muscle cells by inducing cell cycle arrest (48, 49).

The finding that 15-d-PGJ₂ and other deoxy-J₂-IsoPs are generated in vivo via free radical-induced lipid peroxidation has important implications for the pathophysiological role of these compounds. Generation of 15-d-PGJ₂ via the COX pathway has been associated with settings of inflammation (50–52). In the present study, we provide evidence that 15-d-PGJ₂ and 15-d-PGJ₂-like compounds, the deoxy-J₂-IsoPs, are generated in vivo under conditions of oxidant stress. As a result of being generated through the COX and free radical-catalyzed pathways, these compounds may have additive effects in the pathophysiology of diseases, such as atherosclerosis, in which inflammation and oxidant stress are considered to play a critical role (53–56). Previous studies have shown that 15-d-PGJ₂ is synthesized during mammalian inflammatory responses, and its production may represent a feedback mechanism for the resolution of inflammation (50–52). 15-d-PGJ₂ has, in fact, been reported to be present in significant amounts in human atherosclerotic lesions and to reside in foam cells (50). 15-d-PGJ₂ has also been detected in the inflammatory exudates from carrageenan-induced pleurisy in rats, using enzyme immunoassay (51), and it was detected by LC/MS in the cell-free inflammatory exudates of mice during resolving peritonitis (52). Additionally, stimulation of selenium-supplemented murine macrophages with lipopolysaccharide was shown to result in a time-dependent increase in 15-d-PGJ₂ formation, quantified in cell lysates by enzyme immunoassay (57). This suggests that 15-d-PGJ₂ and deoxy-J₂-IsoPs may be produced in vivo in settings of inflammation in which COX activity is increased as well as under conditions of oxidant stress.

Further support for the free radical-catalyzed generation of 15-d-PGJ₂ and other deoxy-J₂-IsoPs in vivo, independent of COX enzymes, was provided by the finding that these compounds are formed in situ esterified in membrane phospholipids in rat liver after induction of oxidant injury by CCl₄. Hydrolysis of deoxy-J₂-IsoPs by bee venom PLA₂ permitted detection and quantification of these compounds by LC/MS/MS. Free 15-d-PGJ₂, which would

be generated through the COX pathway, was not detectable in the liver of control rats and rats treated with CCl_4 . This may be due to the rapid reactivity of 15-d-PGJ₂. Previous studies have indicated that cyclopentenone eicosanoids rapidly undergo conjugation with GSH in vitro and in vivo (26–30). Brunoldi et al. (26) reported that HepG2 cells convert 15-d-PGJ₂ to a GSH conjugate in which the carbonyl on the prostane ring is reduced to a hydroxyl, and the GSH portion of the molecule is subsequently hydrolyzed to a cysteine conjugate. Additionally, Milne et al. (58) showed that the cyclopentenone eicosanoid 15-A₂-IsoP is metabolized primarily in vivo by conjugation with GSH and that the compound is excreted into the urine as the N-acetyl cysteine sulfoxide conjugate of 15-A₂-IsoP in which the carbonyl on the prostane ring of the IsoP is reduced to a hydroxyl. Preliminary studies suggest that, like other cyclopentenone eicosanoids, 15-d-PGJ₂ is rapidly metabolized in vivo via conjugation with GSH and excreted into the urine as a metabolized GSH adduct (data not shown). Further studies are required to identify the major urinary metabolite of 15-d-PGJ₂ to develop a biomarker of its systemic production in humans. These studies are critical to determine to what extent 15-d-PGJ₂ is generated in vivo in humans and elucidate the mechanisms that regulate its production.

In summary, we report the formation of cyclopentenone eicosanoids 15-d-PGJ₂ and deoxy-J₂-IsoPs in vivo via free radical-catalyzed lipid peroxidation, independent of COX. Deoxy-J₂-IsoPs represent a new class of reactive lipid peroxidation products that may exert unique biological actions relevant to the pathobiology of oxidant stress. This study provides the rational basis with which to examine the extent to which deoxy-J₂-IsoPs are generated in vivo in humans. Additionally, future studies aimed at exploring the biological activities of deoxy-J₂-IsoPs will likely yield insights into the pathophysiological consequences of their formation in settings of oxidant stress. 

REFERENCES

- Hardman, J. G., and L. E. Limbird, editors. 2001. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 10th edition. McGraw-Hill Book Co, NY. 669–679.
- Marnett, L. J. 2000. Cyclooxygenase mechanisms. *Curr. Opin. Chem. Biol.* **4**: 545–552.
- Marnett, L. J., S. W. Rowlinson, D. C. Goodwin, A. S. Kalgutkar, and C. A. Lanzo. 1999. Arachidonic acid oxygenation by COX-1 and COX-2. Mechanisms of catalysis and inhibition. *J. Biol. Chem.* **274**: 22903–22906.
- Hamberg, M., and B. Samuelsson. 1966. Prostaglandins in human seminal plasma. Prostaglandins and related factors 46. *J. Biol. Chem.* **241**: 257–263.
- Fitzpatrick, F. A., and M. A. Wynalda. 1983. Albumin-catalyzed metabolism of prostaglandin D₂. Identification of products formed in vitro. *J. Biol. Chem.* **258**: 11713–11718.
- Straus, D. S., and C. K. Glass. 2001. Cyclopentenone prostaglandins: new insights on biological activities and cellular targets. *Med. Res. Rev.* **21**: 185–210.
- Kim, E. H., and Y. Surh. 2006. 15-deoxy- $\Delta^{12,14}$ -Prostaglandin J₂ as a potential endogenous regulator of redox-sensitive transcription factors. *Biochem. Pharmacol.* **72**: 1516–1528.
- Uchida, K., and T. Shibata. 2008. 15-deoxy- $\Delta^{12,14}$ -prostaglandin J₂: an electrophilic trigger of cellular responses. *Chem. Res. Toxicol.* **21**: 138–144.
- Forman, B. M., P. Tontonoz, C. Jasmine, R. P. Brun, B. M. Spiegelman, and R. M. Evans. 1995. 15-deoxy- $\Delta^{12,14}$ -prostaglandin J₂ is a ligand for the adipocyte determination factor PPAR γ . *Cell.* **83**: 803–812.
- Halliwell, B., and J. M. Gutteridge. 1990. Role of free radicals and catalytic metal ions in human disease: an overview. *Methods Enzymol.* **186**: 1–85.
- Southorn, P. A., and G. Powis. 1988. Free radicals in medicine. II. Involvement in human disease. *Mayo Clin. Proc.* **63**: 390–408.
- Ames, B. N. 1983. Dietary carcinogens and anticarcinogens. Oxygen radicals and degenerative diseases. *Science.* **221**: 1256–1264.
- Harman, D. 1981. The aging process. *Proc. Natl. Acad. Sci. USA.* **78**: 7124–7128.
- Morrow, J. D., K. E. Hill, R. F. Burk, T. M. Nammour, K. F. Badr, and L. J. Roberts II. 1990. A series of prostaglandin F₂-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. *Proc. Natl. Acad. Sci. USA.* **87**: 9383–9387.
- Stafforini, D. M., J. R. Sheller, T. S. Blackwell, A. Sapirstein, F. E. Yull, T. M. McIntyre, J. V. Bonventre, S. M. Prescott, and L. J. Roberts II. 2006. Release of free F₂-isoprostanes from esterified phospholipids is catalyzed by intracellular and plasma platelet-activating factor acetylhydrolases. *J. Biol. Chem.* **281**: 4616–4623.
- Morrow, J. D., J. A. Awad, H. J. Boss, I. A. Blair, and L. J. Roberts II. 1992. Non-cyclooxygenase-derived prostanoids (F₂-isoprostanes) are formed in situ on phospholipids. *Proc. Natl. Acad. Sci. USA.* **89**: 10721–10725.
- Pryor, W. A., J. P. Stanley, and E. Blair. 1976. Autoxidation of polyunsaturated fatty acids: II. A suggested mechanism for the formation of TBA-reactive materials from prostaglandin-like endoperoxides. *Lipids.* **11**: 370–379.
- Morrow, J. D., T. M. Harris, and L. J. Roberts II. 1990. Noncyclooxygenase oxidative formation of a series of novel prostaglandins: analytical ramifications for measurement of eicosanoids. *Anal. Biochem.* **184**: 1–10.
- Morrow, J. D., T. A. Minton, C. R. Mukundan, M. D. Campbell, W. E. Zachert, V. C. Daniel, K. F. Badr, I. K. Blair, and L. J. Roberts II. 1994. Free radical-induced generation of isoprostanes in vivo: evidence for the formation of D-ring and E-ring isoprostanes. *J. Biol. Chem.* **269**: 4317–4326.
- Taber, D. F., J. D. Morrow, and L. J. Roberts II. 1997. A nomenclature system for the isoprostanes. *Prostaglandins.* **53**: 63–67.
- Hirata, Y., H. Hayashi, S. Ito, Y. Kikawa, M. Ishibashi, M. Sudo, H. Miyazaki, M. Fukushima, S. Narumiya, and O. Hayaishi. 1988. Occurrence of 9-deoxy- $\Delta^9, \Delta^{12,13,14}$ -dihydroprostaglandin D₂ in human urine. *J. Biol. Chem.* **263**: 16619–16625.
- Bell-Parikh, L. C., T. Ide, J. A. Lawson, P. McNamara, M. Reilly, and G. A. FitzGerald. 2003. Biosynthesis of 15-deoxy- $\Delta^{12,14}$ -PGJ₂ and the ligation of PPAR γ . *J. Clin. Invest.* **112**: 945–955.
- Attallah, A., W. Payakkapan, J. Lee, A. Carr, and E. Brazelton. 1974. PGA: fact, not artifact. *Prostaglandins.* **5**: 69–71.
- Jonsson, H. T., B. S. Middletdich, M. A. Schexnayder, and D. M. Desiderio. 1976. 11,15,19-trihydroxy-9-ketoprost-13-enoic acid and 11,15,19-trihydroxy-9-ketoprost-5, 13-dienoic acid in human seminal fluid. *J. Lipid Res.* **17**: 1–6.
- Chen, Y., J. D. Morrow, and L. J. Roberts II. 1999. Formation of reactive cyclopentenone compounds in vivo as products of the isoprostane pathway. *J. Biol. Chem.* **274**: 10863–10868.
- Brunoldi, E. M., G. Zanoni, G. Vidari, S. Sasi, M. L. Freeman, G. L. Milne, and J. D. Morrow. 2007. Cyclopentenone prostaglandin, 15-deoxy- $\Delta^{12,14}$ -PGJ₂ is metabolized by Hep G2 cells via conjugation with glutathione. *Chem. Res. Toxicol.* **20**: 1528–1535.
- Hubatsch, I., B. Mannervik, L. Gao, L. J. Roberts II, Y. Chen, and J. D. Morrow. 2002. The cyclopentenone product of lipid peroxidation, 15-A₂-isoprostane (8-isoprostaglandin A₂), is efficiently conjugated with glutathione by human and rat glutathione transferase A4–4. *Chem. Res. Toxicol.* **15**: 1113–1118.
- Milne, G. L., G. Zanoni, A. Porta, S. Sasi, G. Vidari, E. S. Musiek, M. L. Freeman, and J. D. Morrow. 2004. The cyclopentenone product of lipid peroxidation, 15-A₂-isoprostane, is efficiently metabolized by HepG2 cells via conjugation with glutathione. *Chem. Res. Toxicol.* **17**: 17–25.
- Cox, B., L. J. Murphey, W. E. Zackert, R. Chinery, R. Graves-Deal, O. Boutaud, J. A. Oates, R. J. Coffey, and J. D. Morrow. 2002. Human colorectal cancer cells efficiently conjugate the cyclopentenone prostaglandin, prostaglandin J₂, to glutathione. *Biochim. Biophys. Acta.* **1584**: 37–45.

30. Atsmon, J., B. J. Sweetman, S. W. Baertschi, T. M. Harris, and L. J. Roberts II. 1990. Formation of thiol conjugates of 9-deoxy- Δ^9, Δ^{12} (E)-prostaglandin D₂ and Δ^{12} (E)-prostaglandin D₂. *Biochemistry*. **29**: 3760–3765.
31. Gao, L., W. E. Zackert, J. J. Hasford, M. E. Danekis, G. L. Milne, C. Remmert, J. Reese, H. Yin, H. Tai, S. K. Dey, et al. 2003. Formation of prostaglandins E₂ and D₂ via the isoprostane pathway: a mechanism for the generation of bioactive prostaglandins independent of cyclooxygenase. *J. Biol. Chem.* **278**: 28479–28489.
32. Yin, H., L. Gao, H. Tai, L. J. Murphey, N. A. Porter, and J. D. Morrow. 2007. Urinary prostaglandin F_{2 α} is generated from the isoprostane pathway and not the cyclooxygenase in humans. *J. Biol. Chem.* **282**: 329–336.
33. Milne, G. L., E. S. Musiek, and J. D. Morrow. 2005. The cyclopentenone (A₂/J₂) isoprostanes—unique, highly reactive products of arachidonic acid peroxidation. *Antioxid. Redox Signal.* **7**: 210–220.
34. Brechbuhl, H. M., E. Min, C. Kariya, B. Frederick, D. Raben, and B. J. Day. 2009. Selective cyclopentenone prostaglandins trigger glutathione efflux and the role of ABCG2 transport. *Free Radic. Biol. Med.* **47**: 722–730.
35. Bishop-Bailey, D., and T. Hla. 1999. Endothelial cell apoptosis induced by the peroxisome proliferator-activated receptor (PPAR) ligand 15-deoxy- $\Delta^{12,14}$ -prostaglandin J₂. *J. Biol. Chem.* **274**: 17042–17048.
36. Levenon, A. L., D. A. Dickinson, D. R. Moellering, R. T. Mulcahy, H. J. Forman, and V. M. Darley-Usmar. 2001. Biphasic effects of 15-deoxy- $\Delta^{12,14}$ -prostaglandin J₂ on glutathione induction and apoptosis in human endothelial cells. *Arterioscler. Thromb. Vasc. Biol.* **21**: 1846–1851.
37. Clay, C. E., A. Monjazeb, J. Thorburn, F. H. Chilton, and K. P. High. 2002. 15-Deoxy-delta12,14-prostaglandin J2-induced apoptosis does not require PPARgamma in breast cancer cells. *J. Lipid Res.* **43**: 1818–1828.
38. Hortelano, S., A. Castillo, A. M. Alvarez, and L. Bosca. 2000. Contribution of cyclopentenone prostaglandins to the resolution of inflammation through potentiation of apoptosis in activated macrophages. *J. Immunol.* **165**: 6525–6531.
39. Rossi, A., P. Kapahi, G. Natoli, T. Takahashi, Y. Chen, M. Karin, and M. G. Santoro. 2000. Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IkappaB kinase. *Nature*. **403**: 103–108.
40. Straus, D. S., G. Pascual, M. Li, J. S. Welch, M. Ricote, C. Hsiang, L. L. Sengchalthalangs, G. Ghosh, and C. K. Glass. 2000. 15-Deoxy- $\Delta^{12,14}$ -prostaglandin J₂ inhibits multiple steps in the NF- κ B signaling pathway. *Proc. Natl. Acad. Sci. U S A.* **97**: 4844–4849.
41. Perez-Sala, D., E. Cernuda-Morollon, E. Pineda-Molina, and F. J. Canada. 2002. Contribution of covalent protein modification to the anti-inflammatory effects of cyclopentenone prostaglandins. *Ann. N. Y. Acad. Sci.* **973**: 533–536.
42. Shiraki, T., N. Kamiya, S. Shiki, T. S. Kodama, A. Kakizuka, and H. Jingami. 2005. α, β -Unsaturated ketone is a core moiety of natural ligands for covalent binding to peroxisome proliferator-activated receptor γ . *J. Biol. Chem.* **280**: 14145–14153.
43. Dinkova-Kostova, A. T., W. D. Holtzclaw, R. N. Cole, K. Itoh, N. Wakabayashi, Y. Katoh, M. Yamamoto, and P. Talalay. 2002. Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants. *Proc. Natl. Acad. Sci. U S A.* **99**: 11908–11913.
44. Itoh, K., M. Mochizuki, Y. Ishii, T. Ishii, T. Shibata, Y. Kawamoto, V. Kelly, K. Sekizawa, K. Uchida, and M. Yamamoto. 2004. Transcription factor Nrf2 regulates inflammation by mediating the effect of 15-deoxy- $\Delta^{12,14}$ -prostaglandin J₂. *Mol. Cell. Biol.* **24**: 36–45.
45. Kim, E. H., D. H. Kim, H. K. Na, and Y. J. Surh. 2004. Effects of cyclopentenone prostaglandins on the expression of heme oxygenase-1 in MCF-7 cells. *Ann. N. Y. Acad. Sci.* **1030**: 493–500.
46. Chen, Z. H., Y. Yoshida, Y. Saito, A. Sekine, N. Noguchi, and E. Niki. 2006. Induction of adaptive response and enhancement of PC12 cell tolerance by 7-hydroxycholesterol and 15-deoxy- $\Delta^{12,14}$ prostaglandin J₂ through up-regulation of cellular glutathione via different mechanisms. *J. Biol. Chem.* **281**: 14440–14445.
47. Zhang, X., L. Lu, C. Dixon, W. Wilmer, H. Song, X. Chen, and B. H. Rovin. 2004. Stress protein activation by the cyclopentenone prostaglandin 15-deoxy- $\Delta^{12,14}$ -prostaglandin J₂ in human mesangial cells. *Kidney Int.* **65**: 798–810.
48. Miwa, Y., T. Sasaguri, H. Inoue, Y. Taba, A. Ishida, and T. Abumiya. 2000. 15-Deoxy-delta(12,14)-prostaglandin J(2) induces G(1) arrest and differentiation marker expression in vascular smooth muscle cells. *Mol. Pharmacol.* **58**: 837–844.
49. Wakino, S., U. Kintscher, S. Kim, F. Yin, W. A. Hsueh, and R. E. Law. 2000. Peroxisome proliferator-activated receptor gamma ligands inhibit retinoblastoma phosphorylation and G1→S transition in vascular smooth muscle cells. *J. Biol. Chem.* **275**: 22435–22441.
50. Shibata, T., M. Kondo, T. Osawa, N. Shibata, M. Kobayashi, and K. Uchida. 2002. 15-Deoxy- $\Delta^{12,14}$ -prostaglandin J₂. A prostaglandin D₂ metabolite generated during inflammatory processes. *J. Biol. Chem.* **277**: 10459–10466.
51. Gilroy, D. W., P. R. Colville-Nash, D. Willis, J. Chivers, M. J. Paul-Clark, and D. A. Willoughby. 1999. Inducible cyclooxygenase may have anti-inflammatory properties. *Nat. Med.* **5**: 698–701.
52. Rajakariar, R., M. Hilliard, T. Lawrence, S. Trivedi, P. Colville-Nash, G. Bellingan, D. Fitzgerald, M. M. Yaqoob, and D. W. Gilroy. 2007. Hematopoietic prostaglandin D₂ synthase controls the onset and resolution of acute inflammation through PGD₂ and 15-deoxy- Δ^{12-14} PGJ₂. *Proc. Natl. Acad. Sci. USA.* **104**: 20979–20984.
53. Berliner, J. A., M. Navab, A. M. Fogelman, J. S. Frank, L. L. Demer, P. A. Edwards, A. D. Watson, and A. J. Luis. 1995. Atherosclerosis: basic mechanisms – oxidation, inflammation, and genetics. *Circulation.* **91**: 2488–2496.
54. Berliner, J., N. Leitinger, A. Watson, J. Huber, A. Fogelman, and M. Navab. 1997. Oxidized lipids in atherogenesis: formation, destruction and action. *Thromb. Haemost.* **78**: 195–199.
55. Heinecke, J. W. 1998. Oxidants and antioxidants in the pathogenesis of atherosclerosis: implications for the oxidized low density lipoprotein hypothesis. *Atherosclerosis.* **141**: 1–5.
56. Chisolm, G. M., and D. Steinberg. 2000. The oxidative modification hypothesis of atherogenesis: an overview. *Free Radic. Biol. Med.* **18**: 1815–1826.
57. Vunta, H., F. Davis, U. D. Palempalli, D. Bhat, R. J. Arner, J. T. Thompson, D. G. Peterson, C. C. Reddy, and K. S. Prabhu. 2007. The anti-inflammatory effects of selenium are mediated through 15-deoxy- $\Delta^{12,14}$ -prostaglandin J₂ in macrophages. *J. Biol. Chem.* **282**: 17964–17973.
58. Milne, G. L., L. Gao, A. Porta, G. Zanoni, G. Vidari, and J. D. Morrow. 2005. Identification of the major urinary metabolite of the highly reactive cyclopentenone isoprostane 15-A₂-Isoprostane *In Vivo*. *J. Biol. Chem.* **280**: 25178–25184.